HUP0204235A2 - Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0204235A2
HUP0204235A2 HU0204235A HUP0204235A HUP0204235A2 HU P0204235 A2 HUP0204235 A2 HU P0204235A2 HU 0204235 A HU0204235 A HU 0204235A HU P0204235 A HUP0204235 A HU P0204235A HU P0204235 A2 HUP0204235 A2 HU P0204235A2
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
group
compositions containing
production inhibitors
Prior art date
Application number
HU0204235A
Other languages
English (en)
Inventor
Helmut Buschmann
Stefanie Frosch
Tieno Germann
Erik Wade
Oswald Zimmer
Original Assignee
Grünenthal GmbH.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH. filed Critical Grünenthal GmbH.
Publication of HUP0204235A2 publication Critical patent/HUP0204235A2/hu
Publication of HUP0204235A3 publication Critical patent/HUP0204235A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Abstract

A találmány (I) általános képletű helyettesített glutárimidekrevonatkozik[mely képletben X jelentése (CH2)n-(CR8R9)p-Z-(CR8R9)m; Zjelentése kénatom, oxigénatom, SO-csoport, SO2-csoport, NR8-csoport,adott esetben N-oxid formájában, vagy CR8R9-csoport; m és p értéke 0vagy 1; n értéke 0, 1, 2 vagy 3; és m, n és p közül legalább az egyik0-tól eltérő jelentésű. A találmány továbbá az (I) általános képletűvegyületek előállítására és gyógyászati hatóanyagént - különösenimmunomodulátorként és antigopátiás és/vagy hematológiai/onkológiaibetegségek inhibitoraként - történő felhasználására vonatkozik. Ó
HU0204235A 2000-01-21 2001-01-09 Substituted glutarimides and use thereof il-12 production inhibitors, process for their preparation and pharmaceutical compositions containing them HUP0204235A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10002509A DE10002509A1 (de) 2000-01-21 2000-01-21 Substituierte Glutarimide
PCT/EP2001/000155 WO2001053261A1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion

Publications (2)

Publication Number Publication Date
HUP0204235A2 true HUP0204235A2 (hu) 2003-03-28
HUP0204235A3 HUP0204235A3 (en) 2005-03-29

Family

ID=7628270

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204235A HUP0204235A3 (en) 2000-01-21 2001-01-09 Substituted glutarimides and use thereof il-12 production inhibitors, process for their preparation and pharmaceutical compositions containing them

Country Status (28)

Country Link
US (2) US6656937B2 (hu)
EP (1) EP1252144B1 (hu)
JP (1) JP2003524641A (hu)
KR (1) KR20020067614A (hu)
CN (1) CN1185215C (hu)
AR (1) AR030185A1 (hu)
AT (1) ATE451355T1 (hu)
AU (1) AU780636B2 (hu)
BR (1) BR0108030A (hu)
CA (1) CA2398061A1 (hu)
CO (1) CO5261626A1 (hu)
CY (1) CY1109784T1 (hu)
DE (2) DE10002509A1 (hu)
DK (1) DK1252144T3 (hu)
ES (1) ES2337875T3 (hu)
HU (1) HUP0204235A3 (hu)
IL (1) IL150813A0 (hu)
MX (1) MXPA02007089A (hu)
NO (1) NO323395B1 (hu)
NZ (1) NZ520759A (hu)
PE (1) PE20011067A1 (hu)
PL (1) PL356986A1 (hu)
PT (1) PT1252144E (hu)
RU (1) RU2278857C2 (hu)
SI (1) SI1252144T1 (hu)
SK (1) SK287173B6 (hu)
WO (1) WO2001053261A1 (hu)
ZA (1) ZA200206664B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
DE10163595A1 (de) * 2001-12-21 2003-08-07 Gruenenthal Gmbh In 3-Position heterocyclisch substituierte Piperidin-2,6-dione
AU2003243272A1 (en) 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
EP1511715A4 (en) * 2002-05-22 2006-05-31 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
AP2006003726A0 (en) 2004-03-17 2006-10-31 Pfizer Prod Inc Novel benzyl(idene)-lactam derivatives
DE102004026703A1 (de) * 2004-05-28 2005-12-29 Grünenthal GmbH Verfahren zur Herstellung von in 3-Position heterocyclisch substituierten Piperidin-2,6-dionen
WO2014107622A1 (en) 2013-01-07 2014-07-10 University Of Southern California Deoxyuridine triphosphatase inhibitors
EA032951B1 (ru) 2013-04-12 2019-08-30 Общество С Ограниченной Ответственностью "Рсв Терапевтикс" Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP6513095B2 (ja) 2014-01-03 2019-05-15 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
EP3319939A1 (en) 2015-07-08 2018-05-16 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
RU2610275C2 (ru) * 2015-07-30 2017-02-08 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
MX2018011216A (es) * 2016-03-16 2019-08-29 H Lee Moffitt Cancer Ct & Res Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
EP3737666A4 (en) * 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
CN107857754B (zh) * 2018-01-15 2018-11-09 泰山医学院 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
CN107903245B (zh) * 2018-01-15 2018-11-13 青岛大学附属医院 一种化合物及其在制备治疗类风湿性关节炎药物中的应用
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
BR112021010484A2 (pt) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Degradadores de irak e usos dos mesmos
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
IL294150A (en) 2019-12-23 2022-08-01 Kymera Therapeutics Inc Smarca joints and their uses
EP4121043A1 (en) 2020-03-19 2023-01-25 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
MA58653B1 (fr) * 2020-06-26 2024-02-29 Valenta Intellekt Ltd Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
US3214431A (en) * 1958-08-04 1965-10-26 Pfizer & Co C Novel glutarimides
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
GB8928043D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
FR2745811B1 (fr) * 1996-03-07 1998-05-22 Sanofi Sa Glutarimide disubstitue procede pour sa preparation, et son utilisation
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE19703763C1 (de) * 1997-02-01 1998-10-01 Gruenenthal Gmbh Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
DE19843793C2 (de) * 1998-09-24 2000-08-03 Gruenenthal Gmbh Substituierte Benzamide
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide

Also Published As

Publication number Publication date
DE10002509A1 (de) 2001-07-26
NO323395B1 (no) 2007-04-23
AU2514001A (en) 2001-07-31
US6656937B2 (en) 2003-12-02
PL356986A1 (en) 2004-07-12
US20030064987A1 (en) 2003-04-03
NO20023319D0 (no) 2002-07-09
HUP0204235A3 (en) 2005-03-29
DE50115252D1 (de) 2010-01-21
US20040048859A1 (en) 2004-03-11
ATE451355T1 (de) 2009-12-15
AR030185A1 (es) 2003-08-13
EP1252144A1 (de) 2002-10-30
EP1252144B1 (de) 2009-12-09
KR20020067614A (ko) 2002-08-22
CO5261626A1 (es) 2003-03-31
PE20011067A1 (es) 2001-12-29
WO2001053261A1 (de) 2001-07-26
SI1252144T1 (sl) 2010-04-30
NO20023319L (no) 2002-09-03
CN1185215C (zh) 2005-01-19
CY1109784T1 (el) 2014-09-10
ES2337875T3 (es) 2010-04-30
RU2002121641A (ru) 2004-01-10
IL150813A0 (en) 2003-02-12
MXPA02007089A (es) 2002-12-13
JP2003524641A (ja) 2003-08-19
SK287173B6 (sk) 2010-02-08
AU780636B2 (en) 2005-04-07
NZ520759A (en) 2005-09-30
ZA200206664B (en) 2004-01-21
RU2278857C2 (ru) 2006-06-27
PT1252144E (pt) 2010-02-03
CA2398061A1 (en) 2001-07-26
DK1252144T3 (da) 2010-04-19
SK10172002A3 (sk) 2003-02-04
CN1394201A (zh) 2003-01-29
BR0108030A (pt) 2003-01-28

Similar Documents

Publication Publication Date Title
HUP0204235A2 (hu) Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
HUP0203836A2 (hu) 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
ATE32728T1 (de) Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel.
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
NO912888L (no) Fremgangsmaate for fremstilling av nye peperidylethere og -thioethere.
ATE316086T1 (de) Clathrat von azithromycin-hydrat mit 1,2- propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
ATE400552T1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)- derivate und sie enthaltende zusammensetzungen
NO20055754L (no) Kolkisosidanaloger
HUP0204394A2 (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DK1501859T3 (da) 17 alfa-fluoralkyl- 11 beta-benzaldoxim-steroider, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse steroider samt deres anvendelse til fremstilling af lægemidler
HUP0300557A2 (hu) N-dezacetiltiokolkicin-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
HUP0300028A2 (en) Thienopyridine derivatives, their production and use and pharmaceutical compositions containing them
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их
HUP0401906A2 (hu) Új katepszin S inhibitor vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0400833A2 (hu) Benzo[g]kinolin-származékok glaukoma és miopia kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0400776A2 (hu) N-(Metiletilaminokarbonil)-4-(3-metilfenilamino)-3-piridilszulfonamid és gyűrűs oligoszacharidok kompozíciói, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20001541L (no) Nye substituerte dimeriske forbindelser, fremgangsmÕte for deres fremstilling og farmasøytiske sammensetninger inneholdende dem
SE9800835D0 (sv) New Compounds
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees